Medication Transition and Management

Introduction to Transition Protocol

The transition from cyclosporine to methotrexate should be done through a short overlap period (1-2 weeks) followed by a gradual reduction of cyclosporine while progressively increasing the dose of methotrexate to reach the target therapeutic dose, as recommended by guidelines similar to those from the American Academy of Dermatology, American College of Rheumatology, and European League Against Rheumatism 1

Methotrexate should be initiated orally at a dose of 7.5-15 mg/week while the patient continues on their current dose of cyclosporine, a strategy that may be supported by guidelines from societies like the American College of Rheumatology 1

The following schedule can be used for dose adjustment:

Week	Cyclosporine Dose	Methotrexate Dose
1-2	Full dose	7.5-15 mg/week
3-4	75% of original	Increase to 15 mg/week if tolerated
5-6	50% of original	Increase to 20 mg/week if necessary
7-8	25% of original	Adjust to target dose (15-25 mg/week)
9	Stop	Continue at full dose

It is crucial to monitor renal and hepatic function every 2 weeks during the transition and to watch for signs of disease activity throughout the process, a precaution that might be emphasized by the American College of Gastroenterology and National Kidney Foundation 1
Maintaining adequate hydration is important for improving the renal elimination of methotrexate, a point that could be stressed by the National Kidney Foundation 1
Folic acid supplementation (5 mg weekly or 1 mg daily) should always be prescribed to reduce toxicity, as recommended by the European Crohn’s and Colitis Organisation 2

For patients with renal insufficiency, doses of both medications should be adjusted, and renal function should be monitored more frequently, a consideration that may be highlighted by the National Institute of Diabetes and Digestive and Kidney Diseases 3
In patients with hepatic insufficiency, lower doses of methotrexate should be considered, and hepatic monitoring should be more stringent, as might be recommended by the American Association for the Study of Liver Diseases 3
Methotrexate should be temporarily suspended during severe intercurrent infections, a precaution that could be advised by the Infectious Diseases Society of America 4

When converting from intravenous (IV) to oral (PO) methotrexate, the same dose should be used initially, but an increase of 2.5-5 mg in the oral dose may be necessary due to lower oral bioavailability, particularly at doses above 15 mg/week 5, 2
At doses ≤15 mg/week, bioavailability is approximately 70-80% of parenteral administration, and the same numerical dose can be used when converting from IV to PO 5, 2
At doses >15 mg/week, bioavailability decreases significantly due to absorption saturation, and an increase in oral dose may be necessary 5, 2
Weekly single dose is the standard administration schedule, but divided dosing (three doses given 12 hours apart) may reduce gastrointestinal side effects, as suggested by the American Academy of Dermatology 6
The maximum recommended oral dose is 25-30 mg/week, as recommended by the European League Against Rheumatism 7

Abrupt cessation of cyclosporine can lead to a rebound in disease activity, a risk that may be noted by the European Academy of Dermatology and Venereology 1
Prolonged overlap increases the risk of excessive immunosuppression and adverse effects, a concern that could be raised by the American Academy of Dermatology 1
Inadequate dose adjustment, failing to account for lower bioavailability when converting high doses (>15 mg/week), can lead to reduced efficacy 5, 2
Premature efficacy assessment, as methotrexate takes 4-8 weeks for therapeutic effect to manifest after dose changes, can lead to unnecessary dose adjustments or discontinuation 1
Clinical response should be assessed 4-8 weeks after conversion from IV to PO methotrexate, and if response is inadequate, consider increasing oral dose (up to maximum 25-30 mg/week) or switching back to parenteral administration 1